Advertisement

Statin and the Risk of Renal-Related Serious Adverse Events: Analysis from the IDEAL, TNT, CARDS, ASPEN, SPARCL, and Other Placebo-Controlled Trials

      A recent study has shown an association between high-potency statins and risk of acute kidney injury. However, these data are from observational studies, and it is not clear if similar signal is seen from randomized controlled trials. We evaluated the risk of renal-associated serious adverse events (SAEs) using statins versus placebo trials and the high-dose versus low-dose statin trials that were available to us. The outcome of interest was renal-related SAEs. The incidence of adverse events relating to kidney injury was determined through review of the adverse event database. The following outcomes were evaluated: (1) renal-related SAEs within 120 days of randomization (primary outcome), (2) renal-related SAEs after 120 days of randomization (secondary), and (3) drug discontinuation due to renal-related SAEs (secondary). There was no difference in the incidence of renal-related SAEs at 120 days (0.04% vs 0.10%, p = 0.162) between atorvastatin and placebo in the 24 placebo-controlled trials (10,345 patients on atorvastatin (10 to 80 mg/day) versus 8,945 patients on placebo) or in the high-dose versus low-dose statin trials including the Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) study (0.05% vs 0.02%, p = 0.625) or the Treating to New Targets (TNT) trial (0.0% vs 0.04%, p = 0.500) trial. Results were similar for renal-related SAEs after 120 days (placebo controlled trials [0.38% vs 0.36%, p = 0.905], IDEAL trial [0.56% vs 0.65%, p = 0.683], or the TNT trial [0.76% vs 1.04%, p = 0.168]) and for drug withdrawal due to renal-related SAE (placebo controlled trials [0.05% vs 0.04%, p = 1.00], IDEAL trial [0.02% vs 0.0%, p = 0.499], or the TNT trial [0.08% vs 0.12%, p = 0.754]). In conclusion, the results from clinical trials with data from 149,882 patient-years of follow-up fail to show any increase in renal-related SAEs with statins compared with controls.
      To read this article in full you will need to make a payment

      References

        • Dormuth C.R.
        • Hemmelgarn B.R.
        • Paterson J.M.
        • James M.T.
        • Teare G.F.
        • Raymond C.B.
        • Lafrance J.P.
        • Levy A.
        • Garg A.X.
        • Ernst P.
        • Canadian Network for Observational Drug Effect S
        Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases.
        BMJ. 2013; 346: f880
        • Stone N.J.
        • Robinson J.
        • Lichtenstein A.H.
        • Merz C.N.
        • Blum C.B.
        • Eckel R.H.
        • Goldberg A.C.
        • Gordon D.
        • Levy D.
        • Lloyd-Jones D.M.
        • McBride P.
        • Schwartz J.S.
        • Shero S.T.
        • Smith Jr., S.C.
        • Watson K.
        • Wilson P.W.
        2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
        Circulation. 2013; (in press)
        • Wanner C.
        • Krane V.
        • Marz W.
        • Olschewski M.
        • Mann J.F.
        • Ruf G.
        • Ritz E.
        • German D.
        • Dialysis Study I.
        Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.
        N Engl J Med. 2005; 353: 238-248
        • Amarenco P.
        • Bogousslavsky J.
        • Callahan 3rd, A.
        • Goldstein L.B.
        • Hennerici M.
        • Rudolph A.E.
        • Sillesen H.
        • Simunovic L.
        • Szarek M.
        • Welch K.M.
        • Zivin J.A.
        • Stroke Prevention by Aggressive Reduction in Cholesterol Levels I
        High-dose atorvastatin after stroke or transient ischemic attack.
        N Engl J Med. 2006; 355: 549-559
        • Knopp R.H.
        • d'Emden M.
        • Smilde J.G.
        • Pocock S.J.
        Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN).
        Diabetes Care. 2006; 29: 1478-1485
        • Colhoun H.M.
        • Betteridge D.J.
        • Durrington P.N.
        • Hitman G.A.
        • Neil H.A.
        • Livingstone S.J.
        • Thomason M.J.
        • Mackness M.I.
        • Charlton-Menys V.
        • Fuller J.H.
        • Investigators C
        Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.
        Lancet. 2004; 364: 685-696
        • LaRosa J.C.
        • Grundy S.M.
        • Waters D.D.
        • Shear C.
        • Barter P.
        • Fruchart J.C.
        • Gotto A.M.
        • Greten H.
        • Kastelein J.J.
        • Shepherd J.
        • Wenger N.K.
        Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
        N Engl J Med. 2005; 352: 1425-1435
        • Pedersen T.R.
        • Faergeman O.
        • Kastelein J.J.
        • Olsson A.G.
        • Tikkanen M.J.
        • Holme I.
        • Larsen M.L.
        • Bendiksen F.S.
        • Lindahl C.
        • Szarek M.
        • Tsai J.
        • Incremental Decrease in End Points through Aggressive Lipid Lowering Study G
        High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.
        JAMA. 2005; 294: 2437-2445
        • Cannon C.P.
        • Braunwald E.
        • McCabe C.H.
        • Rader D.J.
        • Rouleau J.L.
        • Belder R.
        • Joyal S.V.
        • Hill K.A.
        • Pfeffer M.A.
        • Skene A.M.
        • Pravastatin or Atorvastatin E, Infection Therapy-Thrombolysis in Myocardial Infarction I
        Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
        N Engl J Med. 2004; 350: 1495-1504
        • Sarma A.
        The incidence of kidney injury for patients treated with a high-potency versus moderate-potency statin regimen after an acute coronary syndrome.
        American Heart Association Scientific Sessions, Dallas, TX2013
        • de Lemos J.A.
        • Blazing M.A.
        • Wiviott S.D.
        • Lewis E.F.
        • Fox K.A.
        • White H.D.
        • Rouleau J.L.
        • Pedersen T.R.
        • Gardner L.H.
        • Mukherjee R.
        • Ramsey K.E.
        • Palmisano J.
        • Bilheimer D.W.
        • Pfeffer M.A.
        • Califf R.M.
        • Braunwald E.
        • Investigators
        Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial.
        JAMA. 2004; 292: 1307-1316
        • Brunelli S.M.
        • Waikar S.S.
        • Bateman B.T.
        • Chang T.I.
        • Lii J.
        • Garg A.X.
        • Winkelmayer W.C.
        • Choudhry N.K.
        Preoperative statin use and postoperative acute kidney injury.
        Am J Med. 2012; 125: 1195-1204.e3
        • Ho J.E.
        • Waters D.D.
        • Kean A.
        • Wilson D.J.
        • Demicco D.A.
        • Breazna A.
        • Wun C.C.
        • Deedwania P.C.
        • Khush K.K.
        • Investigators TNT
        Relation of improvement in estimated glomerular filtration rate with atorvastatin to reductions in hospitalizations for heart failure (from the Treating to New Targets [TNT] study).
        Am J Cardiol. 2012; 109: 1761-1766
        • Shepherd J.
        • Kastelein J.J.
        • Bittner V.
        • Deedwania P.
        • Breazna A.
        • Dobson S.
        • Wilson D.J.
        • Zuckerman A.
        • Wenger N.K.
        • Investigators TNT
        Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study.
        J Am Coll Cardiol. 2008; 51: 1448-1454